OncoMed announced setbacks in the development of drugs aimed at cancer stem cells: Continue reading
Bad news for anti-stem cell approaches
Leave a reply
OncoMed announced setbacks in the development of drugs aimed at cancer stem cells: Continue reading
OncoMed is developing several compounds that target Wnt and Notch pathways, which are important in cancer and cancer stem cell maintenance, survival, and proliferation. Biomarkers for response of Her-2-negative breast cancer and non-small cell lung cancer (NSCLC) following treatment with Vantictumab, anti-Wnt monoclonal antibody, have been developed. Continue reading